Sustained efficacy of the monoclonal anti-interleukin-1 beta antibody canakinumab in a 9-month trial in Schnitzler's syndrome

Efficacy and safety of the interleukin-1 antagonist rilonacept in Schnitzler syndrome: an open-label study

(2012) K. Krause et al.   ALLERGY

Successful canakinumab treatment identifies IL-1β as a pivotal mediator in Schnitzler syndrome

(2011) Heleen D. de Koning et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Complete remission in 3 of 3 anti-IL-6–treated patients with Schnitzler syndrome

(2011) Karoline Krause et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Canakinumab (ACZ885, a fully human IgG1 anti-IL-1β mAb) induces sustained remission in pediatric patients with cryopyrin-associated periodic syndrome (CAPS)

(2011) Jasmin B Kuemmerle-Deschner et al.   ARTHRITIS RESEARCH & THERAPY

Dramatic response to IL1-RA treatment in longstanding multidrug resistant Schnitzler’s syndrome: a case report and literature review

(2010) Emilio Besada et al.   CLINICAL RHEUMATOLOGY

Treatment of Schnitzler's syndrome with anakinra: report of three cases and review of the literature

(2010) JT Gran et al.   SCANDINAVIAN JOURNAL OF RHEUMATOLOGY

Schnitzler syndrome: response to anakinra in two cases and a review of the literature

(2009) Christian Schuster et al.   INTERNATIONAL JOURNAL OF DERMATOLOGY

In vivo regulation of interleukin 1β in patients with cryopyrin-associated periodic syndromes

(2009) Helen J. Lachmann et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Use of Canakinumab in the Cryopyrin-Associated Periodic Syndrome

(2009) Helen J. Lachmann et al.   NEW ENGLAND JOURNAL OF MEDICINE

IL-1 blockade in Schnitzler syndrome: Ex vivo findings correlate with clinical remission

(2008) John G. Ryan et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY